EV Biologics Statistics
Total Valuation
EV Biologics has a market cap or net worth of 1.03 million.
Market Cap | 1.03M |
Enterprise Value | n/a |
Important Dates
Earnings Date | n/a |
Ex-Dividend Date | n/a |
Share Statistics
EV Biologics has 10.23 million shares outstanding.
Current Share Class | n/a |
Shares Outstanding | 10.23M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | n/a |
Owned by Insiders (%) | n/a |
Owned by Institutions (%) | n/a |
Float | n/a |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 0.03 |
PB Ratio | 0.01 |
P/TBV Ratio | 0.03 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.11, with a Debt / Equity ratio of 0.15.
Current Ratio | 3.11 |
Quick Ratio | 0.80 |
Debt / Equity | 0.15 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | 0.27 |
Financial Efficiency
Return on Equity (ROE) | n/a |
Return on Assets (ROA) | n/a |
Return on Invested Capital (ROIC) | n/a |
Return on Capital Employed (ROCE) | 0.37% |
Revenue Per Employee | n/a |
Profits Per Employee | n/a |
Employee Count | n/a |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -85.59% in the last 52 weeks. The beta is 0.04, so EV Biologics's price volatility has been lower than the market average.
Beta (5Y) | 0.04 |
52-Week Price Change | -85.59% |
50-Day Moving Average | 0.48 |
200-Day Moving Average | 0.80 |
Relative Strength Index (RSI) | 34.97 |
Average Volume (20 Days) | 5,469 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | 0.02 |
Income Statement
In the last 12 months, EV Biologics had revenue of 9.47 million and -551,581 in losses. Loss per share was -0.23.
Revenue | 9.47M |
Gross Profit | 1.54M |
Operating Income | 154,858 |
Pretax Income | -523,987 |
Net Income | -551,581 |
EBITDA | n/a |
EBIT | 154,858 |
Loss Per Share | -0.23 |
Balance Sheet
The company has 12.40 million in cash and 6.47 million in debt, giving a net cash position of 5.94 million or 0.58 per share.
Cash & Cash Equivalents | 12.40M |
Total Debt | 6.47M |
Net Cash | 5.94M |
Net Cash Per Share | 0.58 |
Equity (Book Value) | 42.23M |
Book Value Per Share | 17.52 |
Working Capital | 35.33M |
Cash Flow
Operating Cash Flow | n/a |
Capital Expenditures | n/a |
Free Cash Flow | n/a |
FCF Per Share | n/a |
Margins
Gross margin is 16.24%, with operating and profit margins of 1.63% and -5.82%.
Gross Margin | 16.24% |
Operating Margin | 1.63% |
Pretax Margin | -5.53% |
Profit Margin | -5.82% |
EBITDA Margin | n/a |
EBIT Margin | 1.63% |
FCF Margin | n/a |
Dividends & Yields
EV Biologics does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -0.68% |
Shareholder Yield | -0.68% |
Earnings Yield | -53.30% |
FCF Yield | n/a |
Stock Splits
The last stock split was on November 9, 2017. It was a reverse split with a ratio of 0.2.
Last Split Date | Nov 9, 2017 |
Split Type | Reverse |
Split Ratio | 0.2 |
Scores
EV Biologics has an Altman Z-Score of 1.58. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | 1.58 |
Piotroski F-Score | n/a |